Vanguard Group’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $754K | Sell |
932,570
-76,634
| -8% | -$62K | ﹤0.01% | 3823 |
|
|
2025
Q1 | $775K | Sell |
1,009,204
-1,188
| -0.1% | -$912 | ﹤0.01% | 3784 |
|
|
2024
Q4 | $1.29M | Sell |
1,010,392
-11,378
| -1% | -$14.5K | ﹤0.01% | 3685 |
|
|
2024
Q3 | $2.12M | Buy |
1,021,770
+11,205
| +1% | +$23.2K | ﹤0.01% | 3544 |
|
|
2024
Q2 | $3.85M | Sell |
1,010,565
-6,434
| -0.6% | -$24.5K | ﹤0.01% | 3363 |
|
|
2024
Q1 | $4.82M | Buy |
1,016,999
+10,143
| +1% | +$48.1K | ﹤0.01% | 3313 |
|
|
2023
Q4 | $4.3M | Buy |
1,006,856
+33,250
| +3% | +$142K | ﹤0.01% | 3344 |
|
|
2023
Q3 | $3.01M | Buy |
973,606
+20,668
| +2% | +$63.9K | ﹤0.01% | 3455 |
|
|
2023
Q2 | $4.29M | Buy |
952,938
+36,924
| +4% | +$166K | ﹤0.01% | 3380 |
|
|
2023
Q1 | $5.22M | Buy |
916,014
+16,700
| +2% | +$95.2K | ﹤0.01% | 3290 |
|
|
2022
Q4 | $5.43M | Buy |
899,314
+269
| +0% | +$1.63K | ﹤0.01% | 3264 |
|
|
2022
Q3 | $5.94M | Hold |
899,045
| – | – | ﹤0.01% | 3226 |
|
|
2022
Q2 | $4.69M | Buy |
899,045
+98,547
| +12% | +$514K | ﹤0.01% | 3411 |
|
|
2022
Q1 | $5.52M | Buy |
800,498
+29,058
| +4% | +$200K | ﹤0.01% | 3478 |
|
|
2021
Q4 | $9.6M | Sell |
771,440
-365,282
| -32% | -$4.55M | ﹤0.01% | 3230 |
|
|
2021
Q3 | $35.5M | Buy |
1,136,722
+10,675
| +0.9% | +$334K | ﹤0.01% | 2548 |
|
|
2021
Q2 | $32.2M | Buy |
1,126,047
+258,627
| +30% | +$7.4M | ﹤0.01% | 2593 |
|
|
2021
Q1 | $37.6M | Buy |
867,420
+207,575
| +31% | +$8.99M | ﹤0.01% | 2459 |
|
|
2020
Q4 | $47.2M | Buy |
659,845
+614,845
| +1,366% | +$44M | ﹤0.01% | 2228 |
|
|
2020
Q3 | $1.36M | Buy |
+45,000
| New | +$1.36M | ﹤0.01% | 3593 |
|